Fujian Shengdi Pharmaceutical Co., Ltd.

This Phase 3 trial is testing an injectable drug called HRS9531 in about 9,200 people with atherosclerotic cardiovascular disease (hardened arteries). The goal is to see if it can lower the chance of major heart problems like heart attack, stroke, or death. Participants receive e…

This Phase 2 trial tests two experimental injections, HRS-7249 and SHR-1918, in 108 adults with severely high triglycerides who are at high risk of acute pancreatitis. The study aims to see if these drugs can safely lower fat levels in the blood and reduce the chance of a pancrea…

This Phase 2 trial tests an injectable drug called HRS-9563 in 234 adults with mild to moderate hypertension. Participants are randomly assigned to receive either the drug or a placebo injection. The main goal is to see if HRS-9563 can safely lower average blood pressure over 24 …

This phase 3 trial tests an injectable drug called HRS9531 in 140 obese adults with moderate-to-severe obstructive sleep apnea who already use a breathing machine (PAP). The study aims to see if the drug reduces the number of breathing pauses during sleep and helps with weight lo…

This study tests a new drug called HRS9531 against a placebo in 300 people with type 2 diabetes whose blood sugar is not well controlled with basal insulin. The main goal is to see if HRS9531 lowers blood sugar levels (HbA1c) more effectively after 40 weeks. Participants must be …

This study tests an experimental drug called HRS-5635, given alone or with other medications, in people with chronic hepatitis B. The goal is to lower or clear the hepatitis B surface antigen (HBsAg) from the blood, which could mean better long-term control of the virus. About 36…

This early-stage study tests two versions of an experimental tablet called HRS9531 in people who are overweight or obese. The main goals are to compare how the body absorbs each version and to check for side effects. About 168 men aged 18-55 with a BMI between 24 and 35 will part…

This early-stage study tests a single dose of HRS-2162 injection in 64 healthy volunteers to see if it is safe and how the body processes it. The drug is designed to reverse neuromuscular blockade, a temporary muscle paralysis used during surgery. Researchers will monitor side ef…

This early-stage study tests a new injectable drug called HRS-5817 in healthy adults, some with obesity and some without. The main goal is to check safety and how the body handles the drug, not weight loss. About 92 volunteers will receive either the drug or a placebo to gather i…

This study tests an injectable drug called HRS-9057 in 153 adults hospitalized with heart failure who have fluid retention. The main goal is to see if the drug reduces weight (a sign of fluid loss) by day 8 compared to a placebo. Researchers will also check safety and whether pat…

This study tests an injection called HRS9531 in 140 adults with obstructive sleep apnea and obesity who do not use a CPAP machine. The goal is to see if it improves breathing during sleep and reduces weight over 52 weeks. Participants are randomly assigned to receive the drug or …

This early-stage study looks at how the body processes HRS9531 injection in people with mild or moderate liver issues compared to those with healthy livers. Researchers will measure drug levels and check for side effects in 24 participants. The goal is to understand if liver func…